MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation.
Biomedicines
; 11(7)2023 Jul 02.
Article
em En
| MEDLINE
| ID: mdl-37509518
ABSTRACT
Inhibition of the interaction between MDM2 and p53 has emerged as a promising strategy for combating cancer, including the treatment of glioblastoma (GBM). Numerous MDM2 inhibitors have been developed and are currently undergoing rigorous testing for their potential in GBM therapy. Encouraging results from studies conducted in cell culture and animal models suggest that MDM2 inhibitors could effectively treat a specific subset of GBM patients with wild-type TP53 or functional p53. Combination therapy with clinically established treatment modalities such as radiation and chemotherapy offers the potential to achieve a more profound therapeutic response. Furthermore, an increasing array of other molecularly targeted therapies are being explored in combination with MDM2 inhibitors to increase the effects of individual treatments. While some MDM2 inhibitors have progressed to early phase clinical trials in GBM, their efficacy, alone and in combination, is yet to be confirmed. In this article, we present an overview of MDM2 inhibitors currently under preclinical and clinical investigation, with a specific focus on the drugs being assessed in ongoing clinical trials for GBM patients.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Biomedicines
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos